1 %
Of people have a rare disease
1 %
Of Rare Diseases are Genetic
1 %
Of rare diseases lack an FDA-approved therapy
If you want to go fast, go alone. If you want to go far, go together. We accelerate rare disease research by aligning incentives for fair collaboration at all levels.
Our platform is built from the ground up using cutting-edge encryption technology and state-of-the-art data management approaches. Data privacy and security is at the core of our marketplace.
Our mission is to help relieve human suffering through the creation of a decentralized worldwide network of genomic biobanks that connects biobanks to each other and to researchers. Our core values are connectivity, equity, and privacy.
Query our marketplace for detailed, analysis-ready phenotypic data from diverse populations.
Monetize your data by connecting it to the marketplace. Our state-of-the-art encryption technology ensures no data is exposed unless purchased.
With flexible privacy controls, data is shared according to consent tier: individual-level or only in aggregate.
CEO & Co-Founder
Adam has a PhD in Genetics from Baylor College of Medicine. He previously directed a biomedical innovation consultancy with fortune 500 clients and has led or advised teams for projects related to digital signaling, data mining, molecular diagnostics, and high-throughput functional genetics.
President & Co-Founder
Chris has an MBA and M.S. in Electrical and Computer Engineering from Brigham Young University and five years engineering experience in high speed computing system design. He focused on entrepreneurship and strategy and co-directed a venture studio during his MBA.
Advisor (honorary)
Richard Gibbs is the Founding Director of the Human Genome Sequencing Center (HGSC), established at BCM in 1996. The group was one of the five worldwide sites to undertake and complete the Human Genome Project, culminating in contribution of approximately ten percent of the sequence in 2003.
If you are a clinical laboratory, sequencing center, or rare disease advocacy group, we’d love to hear from you.